John Houston
Chief Executive Officer presso ARVINAS, INC.
Patrimonio netto: 43 M $ in data 31/03/2024
Profilo
John G. Houston ricopre la posizione di presidente, amministratore delegato e direttore di Arvinas, Inc. e presidente, amministratore delegato e direttore di Arvinas Operations, Inc. (una consociata di Arvinas, Inc.). Fa anche parte del consiglio di NextCure, Inc., Cybrexa, Inc. e Oerth Bio LLC. John G. Houston ha occupato in precedenza la posizione di vicepresidente senior-Specialty Discovery alla Bristol Myers Squibb Co. e Head-Lead Discovery Unit alla GlaxoSmithKline Research & Development Ltd. Ha ricevuto un dottorato dall'Università di Glasgow e un dottorato dalla Heriot-Watt University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ARVINAS, INC.
1.52% | 23/02/2024 | 1 036 681 ( 1.52% ) | 43 M $ | 31/03/2024 |
NEXTCURE, INC.
-.--% | 22/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di John Houston
Società | Posizione | Inizio |
---|---|---|
ARVINAS, INC. | Chief Executive Officer | 01/09/2017 |
NEXTCURE, INC. | Director/Board Member | 10/09/2020 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Chief Executive Officer | 21/09/2017 |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Director/Board Member | 03/09/2019 |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky. | Director/Board Member | - |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Connecticut United for Research Excellence, Inc. intends to promote public understanding on the benefits of vaccines and medicines that are being offered by bioscience companies. Its members include biomedical research and educational institutions, biotechnology companies, health professionals, and healthcare systems. The company was founded on August 31, 1990 and is headquartered in New Haven, CT. | Director/Board Member | - |
Bioct Innovation Commons | Director/Board Member | - |
Precedenti posizioni note di John Houston
Società | Posizione | Fine |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/08/2016 |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, GlaxoSmithKline Research & Development Ltd. is a British biopharma company that unites science, technology, and talent to get ahead of disease together. The private company was founded in 1965 and is based in Brentford, UK. GSK's work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer and Shionogi as shareholders. The company is united to do better in various fields, from finance to communications, procurement to HR. GSK provides images and B-roll video for media use and has a privacy notice that applies to any individual who is a current or former registered shareholder of GSK plc. | Corporate Officer/Principal | - |
Formazione di John Houston
University of Glasgow | Doctorate Degree |
Heriot-Watt University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ARVINAS, INC. | Health Technology |
NEXTCURE, INC. | Health Technology |
Aziende private | 6 |
---|---|
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Connecticut United for Research Excellence, Inc. intends to promote public understanding on the benefits of vaccines and medicines that are being offered by bioscience companies. Its members include biomedical research and educational institutions, biotechnology companies, health professionals, and healthcare systems. The company was founded on August 31, 1990 and is headquartered in New Haven, CT. | Commercial Services |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, GlaxoSmithKline Research & Development Ltd. is a British biopharma company that unites science, technology, and talent to get ahead of disease together. The private company was founded in 1965 and is based in Brentford, UK. GSK's work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer and Shionogi as shareholders. The company is united to do better in various fields, from finance to communications, procurement to HR. GSK provides images and B-roll video for media use and has a privacy notice that applies to any individual who is a current or former registered shareholder of GSK plc. | Commercial Services |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky. | Health Technology |
Bioct Innovation Commons |
- Borsa valori
- Insiders
- John Houston